Growth Metrics

Merck (MRK) Asset Writedowns and Impairment (2016 - 2023)

Merck (MRK) has disclosed Asset Writedowns and Impairment for 14 consecutive years, with $779.0 million as the latest value for Q4 2023.

  • Quarterly Asset Writedowns and Impairment fell 1.39% to $779.0 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $2.8 billion through Dec 2023, up 39.36% year-over-year, with the annual reading at $55.0 million for FY2025, 41.03% up from the prior year.
  • Asset Writedowns and Impairment for Q4 2023 was $779.0 million at Merck, down from $790.0 million in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $1.7 billion in Q4 2020, with the low at $15.0 million in Q3 2020.
  • Average Asset Writedowns and Impairment over 5 years is $501.5 million, with a median of $302.0 million recorded in 2021.
  • Peak annual rise in Asset Writedowns and Impairment hit 856.25% in 2020, while the deepest fall reached 97.55% in 2020.
  • Over 5 years, Asset Writedowns and Impairment stood at $176.0 million in 2019, then skyrocketed by 856.25% to $1.7 billion in 2020, then plummeted by 82.06% to $302.0 million in 2021, then soared by 161.59% to $790.0 million in 2022, then decreased by 1.39% to $779.0 million in 2023.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods came in at $779.0 million, $790.0 million, and $887.0 million for Q4 2023, Q4 2022, and Q3 2022 respectively.